Advice
Following a full submission.
Rituximab is accepted for use within NHS Scotland for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with cyclophosphamide, vincristine and prednisolone (CVP) chemotherapy.
Rituximab is for use only by oncologists or haematologists who have expertise in treating lymphoma. It should be administered in a hospital environment where full resuscitation facilities are available. Limited results show that rituximab plus CVP significantly increased the time to treatment failure compared with CVP alone.
Download detailed advice26KB (PDF)
Medicine details
- Medicine name:
- Rituximab (MabThera®)
- SMC ID:
- 135/04
- Indication:
- Follicular lymphoma in combination with CVP chemotherapy
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 13 December 2004